HPV infection a top risk factor for cervical adenocarcinoma worldwide, study says

February 28, 2006

Human papillomavirus (HPV) was found to be the main risk factor associated with increased incidence of an unusual type of cervical cancer called cervical adenocarcinoma, according to a study in the March 1 issue of the Journal of the National Cancer Institute.

The incidence of cervical adenocarcinoma has increased in recent years, even in countries with widespread screening programs, with incidence doubling in relation to all other cervical cancers between 1973 and 1996. HPV is a well-established cause of cervical squamous cell cancer, the most common type of cervical cancer worldwide. Previous studies have suggested HPV may also cause cervical adenocarcinoma, but those studies were small and did not provide information on the role of other factors in the development of this cancer.

To investigate the links between HPV and cervical adenocarcinoma in a multicenter, international sample of women, Xavier Castellsague, M.D., at the Institut Català d'Oncologia in Barcelona, Spain, and colleagues conducted a pooled analysis of eight case-control studies of cervical cancer conducted in countries in Africa, South America, and Southeast Asia. Women had been interviewed to determine potential risk factors for cervical cancer, and all received a pelvic examination as well as testing for HPV and cervical cancer.

Castellsague and colleages found that HPV infection was associated with an 80-fold increase in the risk of cervical adenocarcinoma in the populations studied. Additional risk factors for cervical adenocarcinoma among HPV-positive women included poor hygiene, long-term use of hormonal contraceptives, no schooling, sexual behavior-related variables, and infection with herpes simplex virus 2 (HSV-2). The most common HPV types in women with cervical adenocarcinoma were HPV 16 and 18, which are also the most common types in women who develop the more common type of cervical cancer, squamous cell carcinoma.

The authors suggest that these findings have direct implications for cervical cancer prevention and control. On the basis of the data from this study, they estimated that the two currently most widely tested HPV vaccines, which are designed to prevent infection by HPV 16 and 18, have the potential to prevent up to 86% of all cervical adenocarcinomas worldwide.

"This multi-center study demonstrates the existence of a consistent, strong and robust increased association between infection by high-risk HPV types and risk of development of adenocarcinoma," the authors write.

In an accompanying editorial, Allan Hildesheim, Ph.D., of the National Cancer Institute, and Amy Berrington, D.Phil., of Johns Hopkins University, write, "Despite increases in [adenocarcinoma] rates in recent decades, it would not be unrealistic to expect rates of [adenocarcinoma] to drop in future years, as screening continues to be improved, HPV testing is incorporated into (or in some instances replaces) Pap smear screening programs, and prophylactic HPV16/18 vaccines become available for broad use. The new challenge facing policymakers and the public health community at large is to use the various tools now at our disposal to reduce disease burden associated with [squamous cell carcinoma] and [adenocarcinoma] in the broadest, most rational, and cost-effective manner."

Article: Georgina Llongueres, (34) 93-2607316, pla.comunicacio@ico.scs.es
Editorial: NCI Press Officers, 301-495-6641, ncipressofficers@mail.nih.gov


Article: Castellsague X, Diaz M, de Sanjose S, Munoz M, Herrero R, Franceschi S, et al. The worldwide Human Papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303-315.
Editorial: Hildesheim A, Berrington A. Etiology and Prevention of Cervical Adenocarcinoma. J Natl Cancer Inst 2006; 98:292-293.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.